Investor Call Reveals MRD Test Volumes Surging 38% QoQ, Only 10% of Sales Force Deployed, and 2027 Profitability Target Intact After Personalis Acquisition
TEM sits 16% above its 52-week low of $41.73.
Summary
Tempus AI's investor call on the Personalis acquisition revealed MRD test volumes growing 38% QoQ to ~9,000 in Q2 2026, with only 10% of the sales force deployed, and reaffirmed a 2027 profitability target. The deal adds a best-in-class tumor-informed MRD assay to Tempus's portfolio, with significant commercial and data synergies ahead.
Key Events · M&A and Partnerships · TEM
-
MRD Test Volumes Surge 38% QoQ
NeXT Personal test volumes distributed by Tempus reached ~9,000 in Q2 2026, up from ~6,500 in Q1 2026, a 38% quarter-over-quarter increase. This growth occurred with only 10% of Tempus's sales force actively selling MRD solutions.
-
Acquisition Price and Structure
Tempus will acquire all outstanding Personalis shares not already owned for $16.25 per share, a 6% premium to the prior close and 28% premium to the 30-day VWAP. Consideration is 100% stock with a floating exchange ratio capped at 0.3356 TEM shares per PSNL share; Tempus has the option to pay up to 50% in cash.
-
2027 Profitability Target Reaffirmed
Management stated that even with the acquisition, Tempus intends to be EBITDA and free cash flow positive in 2027, absorbing Personalis's near-term losses through growing gross profit dollars from the core therapy selection and data businesses.
-
Strategic Data and Commercial Synergies
Post-close, Tempus will integrate Personalis's longitudinal MRD data into its multimodal data flywheel, enhancing biopharma insights for biomarker discovery, patient selection, and trial optimization. The combined portfolio offers a complete suite from hereditary risk to therapy selection to recurrence monitoring.
Analysis · TEM · Industrial Applications And Services
This investor call transcript adds critical new details to the $1.5 billion Personalis acquisition announced earlier today. Tempus disclosed that its distributed NeXT Personal MRD test volumes jumped 38% quarter-over-quarter to ~9,000 tests in Q2 2026, yet only 10% of its sales force is currently selling MRD — signaling massive untapped growth potential as reimbursement expands. Management confirmed the combined company remains on track for EBITDA and free cash flow positivity in 2027, absorbing Personalis's near-term losses through core business gross profit growth. The floating exchange ratio (max 0.3356 TEM shares per PSNL share) and Tempus's option to pay up to 50% cash provide deal structure clarity. The call also underscored the strategic data flywheel benefits: integrating Personalis's longitudinal MRD data with Tempus's AI models to enhance biopharma offerings. These specifics transform the acquisition from a headline into a quantifiable growth and synergy story.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 41.4% of the 440 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TEM was trading at $48.53 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8.7B. The 52-week trading range was $41.73 to $104.32. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.